Treatment satisfaction is associated with improved quality of life in patients treated with inhaled treprostinil for pulmonary arterial hypertension

Health and Quality of Life Outcomes

Volumn 11, Issue 1, 2013, Pages

  Chen, Hubert ^a,b   Rosenzweig, Erika B ^c   Gotzkowsky, S Karl ^d   Arneson, Carl ^d   Nelsen, Andrew C ^d   Bourge, Robert C ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GENENTECH INC   (United States)

^c Columbia University ^*  (United States)

^d UNITED THERAPEUTICS CORPORATION   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Iloprost; Inhaled prostacyclin; Pulmonary arterial hypertension; Quality of life; Treatment satisfaction; Treprostinil

Indexed keywords

ILOPROST; TREPROSTINIL;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EFFICACY; FEMALE; FUNCTIONAL STATUS; HUMAN; INTERNAL CONSISTENCY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT SATISFACTION; PSYCHOMETRY; PULMONARY HYPERTENSION; QUALITY OF LIFE; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME; TREATMENT SATISFACTION QUESTIONNAIRE FOR MEDICATION; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; DRUG ADMINISTRATION SCHEDULE; EPOPROSTENOL; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; PATIENT SATISFACTION; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 84874533332     PISSN: None     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/1477-7525-11-31     Document Type: Article

References (28)

1. D'Alonzo GE, Barst RJ, Ayres SM. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991, 115:343-349.
2. Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from reveal. Chest 2012, 142:448-456.
3. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002, 106:1477-1482.
4. McLaughlin VV, Sitbon O, Badesch DB. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005, 25:244-249.
5. Chen H, Taichman DB, Doyle RL. Health-related quality of life and patient-reported outcomes in pulmonary arterial hypertension. Proc Am Thorac Soc 2008, 5:623-630.
6. Shafazand S, Goldstein MK, Doyle RL, Hlatky MA, Gould MK. Health-related quality of life in patients with pulmonary arterial hypertension. Chest 2004, 126:1452-1459.
7. Taichman DB, Shin J, Hud L. Health-related quality of life in patients with pulmonary arterial hypertension. Respir Res 2005, 6:92.
8. Chen H, Kobashigawa EA, Blanc PD, De Marco T, Napoles-Springer A. A qualitative approach to understanding quality of life impairment in pulmonary arterial hypertension: getting beyond the numbers. Am J Respir Crit Care Med 2011, 183:A5926.
9. Flattery MP, Pinson JM, Savage L, Salyer J. Living with pulmonary artery hypertension: patients' experiences. Heart Lung 2005, 34:99-107.
10. Hall H, Cote J, McBean A, Purden M. The experiences of patients with pulmonary arterial hypertension receiving continuous intravenous infusion of epoprostenol (Flolan) and their support persons. Heart Lung 2012, 41:35-43.
11. Barst RJ, Gibbs JS, Ghofrani HA. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009, 54:S78-S84.
12. Actelion Pharmaceuticals Ltd VENTAVIS (iloprost) inhalation solution 2011, United States Food and Drug Administration Drug Product Label, http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#labelinfo, Actelion Pharmaceuticals Ltd.
13. United Therapeutics Corporation TYVASO (treprostinil) inhalation solution 2011, United States Food and Drug Administration Drug Product Label, http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#labelinfo, United Therapeutics Corporation.
14. McLaughlin VV, Benza RL, Rubin LJ. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 2010, 55:1915-1922.
15. McLaughlin VV, Oudiz RJ, Frost A. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006, 174:1257-1263.
16. Olschewski H, Simonneau G, Galie N. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002, 347:322-329.
17. Bourge RC, Tapson V, Safdar Z. Safely transitioning from inhaled iloprost to inhaled treprostinil sodium - results from a multicenter open-label study in patients with pulmonary arterial hypertension. J Heart Lung Transpl 2011, 30:S71-S72.
18. Bourge RC, Tapson VF, Safdar Z. Rapid transition from inhaled iloprost to inhaled treprostinil in patients with pulmonary arterial hypertension. Cardiovasc Ther 2013, 31:38-44.
19. Atkinson MJ, Sinha A, Hass SL. Validation of a general measure of treatment satisfaction, the treatment satisfaction questionnaire for medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2004, 2:12.
20. Revicki DA. Patient assessment of treatment satisfaction: methods and practical issues. Gut 2004, 53(Suppl 4):iv40-iv44.
21. Shikiar R, Rentz AM. Satisfaction with medication: an overview of conceptual, methodologic, and regulatory issues. Value Health 2004, 7:204-215.
22. Weaver M, Patrick DL, Markson LE, Martin D, Frederic I, Berger M. Issues in the measurement of satisfaction with treatment. Am J Manag Care 1997, 3:579-594.
23. Atkinson MJ, Kumar R, Cappelleri JC, Hass SL. Hierarchical construct validity of the treatment satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy consumers. Value Health 2005, 8(Suppl 1):S9-S24.
24. Atkinson MJ, Lennox RD. Extending basic principles of measurement models to the design and validation of patient reported outcomes. Health quality life outcomes 2006, 4:65.
25. Bharmal M, Payne K, Atkinson MJ, Desrosiers MP, Morisky DE, Gemmen E. Validation of an abbreviated treatment satisfaction questionnaire for medication (TSQM-9) among patients on antihypertensive medications. Health Qual Life Outcomes 2009, 7:36.
26. McKenna SP, Doughty N, Meads DM, Doward LC, Pepke-Zaba J. The cambridge pulmonary hypertension outcome review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension. Qual Life Res 2006, 15:103-115.
27. McKenna SP, Doward LC. The needs-based approach to quality of life assessment. Value Health J Inter Soc Pharmacoecon Outcomes Res 2004, 7(Suppl 1):S1-S3.
28. Minai OA, Chen H, Parambil J. Safety, efficacy and treatment satisfaction following rapid switch from epoprostenol to IV treprostinil in stable pulmonary arterial hypertension patients. Am J Respir Crit Care Med 2008, 177:A259.